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ABSTRACT 
Graft-versus-host disease (GVHD) is a frequent complication following allogeneic 
hematopoietic stem cell transplantation (HSCT) with current therapies limited to general 
immunosuppression. Humanized mouse models of GVHD are emerging as valuable 
intermediaries to allow translation of findings from allogeneic mouse models to humans to 
prevent and treat this disease, but such models require further characterisation. In this study, 
humanized mice were generated by injecting immunodeficient non-obese diabetic severe 
combined immunodeficiency interleukin-2 receptor γ common chain null (NSG) mice with 
human peripheral blood mononuclear cells (hPBMCs). Clinical GVHD development was 
assessed using established scoring criteria (weight loss, posture, activity, fur texture and skin 
integrity). Differences between humanized NSG mice that developed clinical or subclinical 
GVHD were then compared. Both groups of mice demonstrated similar frequencies of human 
leukocyte engraftment. In contrast, mice that developed clinical GVHD demonstrated 
increased histological damage compared to mice with subclinical GVHD. Furthermore, mice 
with clinical GVHD exhibited increases in the splenic human CD4+:CD8+ T cell ratio, serum 
human interferon (IFN)-γ and intestinal human interleukin (IL)-17 expression compared to 
mice with subclinical GVHD. These cellular and molecular changes could be used as 
potential markers of disease progression in this preclinical model. This study also provides 
further insights into GVHD development which may be relevant to human HSCT recipients. 
 
HIGHLIGHTS: 
• GVHD development in humanized mice is variable with the majority developing clinical 
disease but a small proportion with subclinical disease. 
• Mice with clinical GVHD demonstrate increased splenic human CD4+:CD8+ T cell ratios 
compared to mice with subclinical GVHD. 
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• Mice with clinical GVHD exhibit increased serum human interferon (IFN)-γ and 
intestinal human interleukin (IL)-17 expression compared to mice with subclinical 
GVHD. 
 
KEYWORDS 
Xenogeneic graft-versus-host disease, humanized mice, interferon-gamma, interleukin-17, T 
lymphocyte 
 
ABBREVIATIONS 
APC, Allophycocyanin; ANOVA, one-way analysis of variance; FITC, fluorescein 
isothiocyanate; FoxP3, forkhead box P3; GVHD, graft-versus-host disease; h, human: 
hPBMCs, human peripheral blood mononuclear cells; HSCT, hematopoietic stem cell 
transplantation; IFN, interferon; IL, interleukin; mAb, monoclonal antibody; m, murine; 
MST, median survival time; NSG, non-obese diabetic severe combined immunodeficiency 
interleukin-2 receptor γ common chain null; PE, R-phycoerythrin; Per-CP, peridinin 
chlorophyll protein; qPCR, quantitative real-time PCR; TNF-α, tumour necrosis factor alpha; 
Treg, regulatory T cell. 
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1. INTRODUCTION 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for 
haematological malignancies and other blood disorders. However, graft-versus-host disease 
(GVHD) occurs in approximately half of the HSCTs conducted annually [1] and leads to a 
mortality rate of approximately 20% in these patients [2]. GVHD emerges when effector 
donor T cells mount an immune response against host tissues [3]. GVHD is characterized by 
three stages. The first stage is release of danger signals from cells damaged by the underlying 
disease and/or conditioning regimes, followed by CD4+ T cell activation by antigen 
presenting cells resulting in cytokine release, and finally CD4+ and CD8+ T cell-mediated 
inflammatory damage [4,5]. This damage can be propagated by the “cytokine storm” in the 
latter stage, wherein Th1 and Th17 cells release pro-inflammatory cytokines such as 
interferon (IFN)-γ [4,5] and interleukin (IL)-17 [6,7], respectively, perpetuating a feed 
forward loop of inflammation. Conversely, regulatory T (Treg) cells can modulate effector T 
cells to reduce T cell-mediated inflammatory damage in GVHD [8]. Current therapies for 
GVHD are limited, with the standard therapy being general immunosuppression achieved 
through steroids, leaving patients susceptible to subsequent infections and/or disease relapse 
[9]. Therefore, greater understanding of the mechanisms important in GVHD and elucidation 
of new therapies is essential to improve outcomes in HSCT patients and prevent GVHD.  
Current studies into potential therapeutics for GVHD are investigated in allogeneic mouse 
models before translation to the clinic. However, potentially due to large species differences 
between humans and mice, therapies that delay or prevent GVHD in allogeneic mouse 
models often do not translate to the clinic. To address this, previous studies have developed a 
range of preclinical “humanized” mouse models [10]. The most commonly used of these 
models is the humanized immunodeficient non-obese diabetic severe combined 
immunodeficiency interleukin-2 receptor γ common chain null (NSG) mouse, developed by 
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Shultz et al. [11] wherein mice readily engraft human peripheral blood mononuclear cells 
(hPBMCs) due to three defects. First, the Scid mutation prevents V(D)J recombination to 
impair B and T cell development [12]. Second, deletion of the Il2rg gene results in absence of 
natural killer (NK) cells. Third, a polymorphism in the Sirpa gene, present due to 
backcrossing onto a NOD background, promotes phagocytic tolerance of xenogeneic 
leukocytes [13]. Human T cells recognize major histocompatibility complex (MHC) class I 
and II of NSG mice to cause GVHD in this humanized mouse model [14], demonstrating that 
human T cell responses can be investigated in vivo to better understand this disease in a 
preclinical setting.  
The humanized NSG model of GVHD is emerging as a valuable intermediate to allow 
translation of findings identified in allogeneic mouse models to human clinical trials. For 
example, based on an earlier study in an allogeneic mouse model of GVHD [15], King, et al. 
[14] demonstrated tumour necrosis factor (TNF)-α blockade could reduce GVHD severity in 
this humanized mouse model, and etanercept, an anti-TNF-α monoclonal antibody (mAb) has 
subsequently shown efficacy in clinical trials [16]. More recently, Burger et al. [17] 
demonstrated an anti-CCR5 mAb (PRO 140) could reduce GVHD in humanized NSG mice, 
with this mAb now being investigated in clinical trials [18]. Finally, the discovery of Treg 
cells, and their therapeutic potential in GVHD has progressed from allogeneic mouse models 
[8], to humanized NSG models [19,20], and finally to clinical trials [21]. Moreover, this 
model has helped elucidate the action of post-transplant cyclophosphamide on Treg cells in 
GVHD development [22]. Therefore, the humanized NSG model offers a valid preclinical 
model to test therapies for translation to the clinic. Although this mouse model has offered 
numerous advancements, the characterization of GVHD in these mice has not been 
adequately described.  
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2. OBJECTIVE 
The current study aimed to investigate the characteristics of GVHD that were observed in 
humanized NSG mice injected with human PBMCs that developed clinical disease compared 
to those mice that displayed subclinical GVHD. This study demonstrated that all humanized 
NSG mice had similar engraftment of human leukocytes, which were predominantly T cells. 
In contrast, humanized NSG mice with clinical GVHD demonstrated greater splenic 
CD4+:CD8+ T cells ratios, serum human IFN-γ concentrations and intestinal human IL-17 
expression than humanized mice with subclinical GVHD. These cellular and molecular 
changes could potentially be used as biomarkers of disease progression in this preclinical 
model and provide insights into GVHD development which may be applicable to human 
HSCT recipients. 
 
3. MATERIALS AND METHODS 
3.1. Antibodies for flow cytometry 
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-hCD4 (clone: RPA-T4), and 
mouse anti-hCD45 (clone: HI30); R-phycoerythrin (PE)-conjugated mouse anti-hCD3 (clone: 
UCHT1) and mouse anti-hCD8 (clone: RPA-T8); peridinin chlorophyll protein 
(PerCP)-Cy5.5 conjugated mouse anti-hCD4 (clone: L200) and rat anti-mCD45 (clone: 30-
F11); and allophycocyanin (APC)-conjugated mouse anti-hCD3 (clone: UCHT1) and mouse 
anti-hCD19 (clone: HIB19) mAb were obtained from BD (San Jose, CA, USA). 
3.2. Mice 
All mouse experiments were conducted in accordance with approval by the Animal Ethics 
Committee, University of Wollongong (Wollongong, Australia). Female NSG mice, 
originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA), were bred at the 
Westmead Animal Research Facility (Westmead, Australia) or Australian BioResources 
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(Moss Vale, Australia). NSG mice, obtained at 6-10 weeks of age, were housed in filter top 
cages in Tecniplast (Buggugiate, Italy) isolation cabinets, and provided with autoclaved food 
and water, ad libitum. Mice were allowed to acclimatize for one week prior to injection.  
3.3. Isolation of human PBMCs  
All experiments with human blood were conducted in accordance with approval by the 
Human Ethics Committee, University of Wollongong. Peripheral blood was collected by 
venepuncture into VACUETTE® lithium heparin tubes (Greiner Bio-One; Frickenhausen, 
Germany). Whole blood, diluted with an equal volume of sterile phosphate buffered saline 
(PBS) (Thermo Fisher Scientific, Waltham, USA), was underlaid with Ficoll-Paque PLUS 
(GE Healthcare; Uppsala, Sweden) and centrifuged (560 x g for 30 min). hPBMCs were 
collected and washed with PBS (430 x g for 5 min) and resuspended in PBS.  
3.4. Humanized NSG mouse model of GVHD 
NSG mice were injected intra-peritoneally (i.p) with 10 x 106 hPBMCs (from the same 
donor) in 100 μL sterile PBS (hPBMC group) or with 100 μL sterile PBS alone (control 
group) (day 0). Mice were checked for engraftment of hPBMCs at 3 weeks post-injection by 
immunophenotyping tail blood. Mice were monitored up to week 8 for signs of GVHD using 
a scoring system [23] giving a total clinical score out of 10 (Table 1). Mice were euthanized 
at end-point either 8 weeks post-injection or earlier if exhibiting a clinical score of ≥ 8 or a 
weight loss of ≥ 10%, according to the approved animal ethics protocol.  
3.5. Immunophenotyping by flow cytometry 
Tail blood (20-30 μL) was collected 3 weeks post-hPBMC injection into 200 μL of citrate 
solution (Sigma-Aldrich), diluted with PBS and centrifuged (500 x g for 5 min). Spleens from 
euthanized mice at end-point were mechanically dissociated, filtered through 70 μm nylon 
filters (Falcon Biosciences, New York, NY, USA) and centrifuged (300 x g for 5 min). Blood 
and spleen cells were incubated with ammonium chloride potassium (ACK) lysis buffer (150 
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mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2CO3, pH 7.3) for 5 min and washed in PBS (300 x g 
for 5 min). Cells were then washed in PBS containing 2% foetal bovine serum (300 x g for 3 
min), and incubated for 30 min with fluorochrome-conjugated mAb, including respective 
isotype controls. Cells were washed with PBS (300 x g for 3 min) and data was collected 
using a BD LSRII Flow Cytometer (using band pass filters 515/20 for FITC, 575/26 for PE, 
675/40 for PerCP-Cy5.5, and 660/20 for APC). The relative percentages of cells were 
analyzed using FlowJo software v8.7.1 (TreeStar Inc., Ashland, OR, USA).  
3.6. Histological analysis 
Tissues from euthanized mice at end-point were incubated overnight in neutral buffered 
(10%) formalin (Sigma-Aldrich). Fixed tissues were removed, coated in paraffin, sectioned (5 
μm) and stained with haematoxylin and eosin (POCD; Artarmon, Australia). Histological 
changes were assessed using a Leica (Wetzlar, Germany) DMRB microscope and Leica 
Application Software version 4.3. 
3.7. RNA isolation and cDNA synthesis 
Tissues from euthanized mice at end-point or freshly isolated hPBMCs were stored in 
RNAlater (Sigma-Aldrich) at -20°C. RNA was isolated using TRIzol reagent (Thermo Fisher 
Scientific) as per the manufacturer’s instructions. Isolated RNA was immediately converted 
to complementary DNA (cDNA), using the qScript cDNA Synthesis Kit (Quanta 
Biosciences, Beverly, MA, USA) as per the manufacturer’s instructions, and RNA stored at -
80°C. cDNA was checked by PCR amplification of the house keeping gene glyceraldehyde 
3-phosphate dehydrogenase (Invitrogen, Carlsbad, CA, USA) for 35 cycles (95°C for 1 min, 
55°C for 1 min, and 72°C for 1 min) and a holding temperature of 4°C. Purity and size of 
amplicons were confirmed by 2% agarose gel electrophoresis.  
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3.8. Quantitative real-time PCR  
Quantitative real-time PCR (qPCR) reactions of cDNA samples were using TaqMan 
Universal Master Mix II (Thermo Fisher Scientific) according to the manufacturer’s 
instructions, with VIC-labelled human hypoxanthine phosphoribosyl transferase 1 
(Hs99999909_m1) and FAM-labelled hIFN-γ (Hs00989291_m1), hIL-17 (Hs00936345_m1) 
and hFoxP3 (Hs01085834_m1) primers (Thermo Fisher Scientific). qPCR cycles consisted of 
two initial steps of 50°C for 2 min, and 95°C for 10 min and 40 cycles of 95°C for 15 s, and 
60°C for 1 min. Reactions were conducted in triplicate using a Roche Diagnostics 
(Indianapolis, IN, USA) LightCycler 480, and analysis was conducted using LightCycler480 
software v1.5.1. Human gene expression is shown relative to expression in cDNA from 
freshly isolated donor hPBMCs. 
3.9. ELISA 
Blood, collected via cardiac puncture from euthanized mice at end-point, was incubated for 1 
h at RT and centrifuged (1,700 x g for 10 min). Supernatants were re-centrifuged (1,700 x g 
for 10 min) and sera stored at -80°C. Serum cytokine concentrations were measured using a 
hIFN-γ Ready-Set-Go! ELISA Kit (eBioscience, San Diego, CA, USA) as per the 
manufacturer’s instructions. Absorbances (450 and 570 nm) were measured using a 
SpectraMax Plus 384 (Molecular Devices, Sunnyvale, CA, USA). 
3.10. Statistical Analysis 
Data is given as mean ± standard error of the mean (SEM). Statistical differences were 
calculated using Student’s t-test for single comparisons or one-way analysis of variance 
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score 
were analyzed using a repeated measures two-way ANOVA with Tukey’s post-hoc test for 
multiple comparisons. Median survival times (MST) were compared using the log-rank 
(Mantel-Cox) test. Proportions of mice sacrificed prior to week 8 (mortality rates) were 
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compared using Fisher’s Exact test. All statistical analyses and graphs were generated using 
GraphPad Prism 5 for PC (GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered 
significant for all tests. 
 
4. RESULTS 
4.1. Clinical GVHD development varies in humanized NSG mice 
NSG mice, injected i.p. with either saline (control) or hPBMCs, were monitored for physical 
manifestations of GVHD over 8 weeks. After 4 weeks, humanized NSG mice with GVHD 
started to exhibit clinical signs of disease (Fig 1A). By end-point it became apparent that 
hPBMC-injected mice segregated into one of two groups based on clinical score (Table 1); 
one group with scores ≥ 3 (clinical GVHD) and another group with scores < 3 (subclinical 
GVHD) (Fig 1A). Mice with clinical scores ≥ 3 exhibited weight loss, reduced activity, 
postural changes (hunching) and fur ruffling, with skin involvement in some mice, whilst 
mice with clinical scores < 3 was solely attributed to fur ruffling and/or postural changes 
(data not shown). The mean clinical score over the course of the experiment in humanized 
mice with clinical GVHD was greater than both control mice and mice with subclinical 
GVHD (P < 0.0001 and P = 0.0010, respectively) (Fig 1A). Weight loss alone is indicative of 
GVHD development [24]. Notably, control mice and humanized mice with subclinical 
GVHD continued to gain weight over the entire 8 weeks, however, humanized mice with 
clinical GVHD started to lose weight after 4 weeks (Fig 1B). Although this difference was 
obvious after 4 weeks, the weight loss was not statistically significant between groups (P = 
0.2871). Humanized mice with clinical GVHD had a MST of 50 days, which was 
significantly worse than control mice (P < 0.0001) and humanized mice with subclinical 
GVHD (P < 0.0001) where all mice survived for 8 weeks (Fig 1C). Humanized mice with 
clinical GVHD exhibited an 80% mortality rate over 8 weeks, which was significantly greater 
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than control mice (P < 0.0001) or humanized mice with subclinical GVHD (P = 0.0350) (Fig 
1C).  
4.2. Increased histological damage and leukocyte infiltration is associated with 
clinical GVHD 
GVHD targets the liver, gastro-intestinal tract and skin in humanized NSG mice [14,23], 
similar to humans [5]. To compare control NSG mice and humanized NSG mice with clinical 
or subclinical GVHD, histological analyses of target tissues were conducted, as well as 
spleens to examine evidence of engraftment at end-point. As expected, control mice 
demonstrated normal architecture and minimal presence of leukocytes in spleens, livers, 
small intestines and skin (Fig 2). Both humanized NSG mice with subclinical or clinical 
GVHD demonstrated leukocyte infiltration in spleens (Fig 2), consistent with engraftment of 
hPBMCs. However, mice with subclinical GVHD demonstrated leukocyte infiltration and 
minor apoptosis in the liver, whilst mice with clinical GVHD demonstrated greater leukocyte 
infiltration and greater apoptosis compared to both control mice and humanized mice with 
subclinical GVHD (Fig 2). Humanized mice with subclinical GVHD demonstrated leukocyte 
infiltration and minor damage to enterocytes and occasional crypt epithelial cell apoptosis in 
the small intestine (Fig 2). Humanized mice with clinical GVHD demonstrated increased 
leukocyte infiltration and structural damage including rounding of villi, enterocyte loss and 
crypt epithelial cell apoptosis in the small intestine compared to mice with subclinical GVHD 
(Fig 2). Humanized mice with subclinical GVHD demonstrated similar intact architecture and 
leukocyte infiltration to control mice in the skin, except for separation at the dermal 
subcutaneous boundary in the former group (Fig 2). The skin of humanized mice with clinical 
GVHD demonstrated leukocyte infiltration, epidermal thickening, basal epithelial cell 
apoptosis and dermal-subcutaneous boundary separation (Fig 2).  
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4.3. Similar engraftment of hPBMCs in mice with subclinical and clinical GVHD 
To confirm that NSG mice injected with hPBMCs engrafted human leukocytes, blood was 
collected at 3 weeks post-injection and spleens were collected at end-point and analyzed by 
flow cytometry. Blood (Fig 3A-D) and spleens (Fig 3E-J) revealed both murine (m) and 
human (h) CD45+ cells in hPBMC-injected mice (Fig 3A, E). As expected, control mice 
demonstrated mCD45+ but no hCD45+ cells in the blood and spleen (Fig 1B, F).  
The frequency of hCD45+ leukocytes were calculated as a percentage of total hCD45+ and 
mCD45+ cells. In the blood, mean hCD45+ engraftment was similar between mice with 
subclinical GVHD (15.1 ± 2.2 %, n = 3) and mice with clinical GVHD (15.3 ± 3.2, n = 10) (P 
= 0.9737) (Fig 3B). hCD45+ cells in the blood of hPBMC-injected mice were then analyzed 
for the presence of hCD3+ (human T cells) and hCD19+ cells (human B cells) (Fig 3A). NSG 
mice injected with hPBMCs showed the majority of engrafted human leukocytes were T 
cells. The mean percentage of T cells in blood did not differ between mice with subclinical 
GVHD (99.1 ± 0.1%, n = 3) or clinical GVHD (98.1 ± 0.4%, n = 10) (P = 0.1500) (Fig 3C). 
The remaining cells in the blood were hCD3- and hCD19-, the frequencies of which did not 
differ between mice with subclinical GVHD (0.8 ± 0.1%, n = 3) or clinical GVHD (1.8 ± 
0.4%, n = 10) (P = 0.1869) (Fig 3D).  
Similar to blood, mean hCD45+ engraftment in spleens at end-point was similar between 
mice with subclinical GVHD (90.9 ± 1.7%, n = 3) and clinical GVHD (87.7 ± 2.9%, n = 10, 
respectively) (P = 0.5880) (Fig. 3F). Moreover, NSG mice injected with hPBMCs showed the 
majority of engrafted human leukocytes in spleens were T cells. The mean percentage of T 
cells in spleens did not differ between mice with subclinical GVHD (97.8 ± 0.5%, n = 3) or 
clinical GVHD (98.4 ± 0.2%, n = 10) (P = 0.1942) (Fig 3G). The remaining cells in spleens 
were hCD3- and hCD19-, the frequencies of which did not differ between mice with 
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subclinical GVHD (2.2 ± 0.5%, n = 3) or clinical GVHD (1.6 ± 0.2%, n = 10) (P = 0.1942) 
(Fig 3H).  
Further analysis of the splenic human T cells (hCD3+ hCD19- cells) (Fig 3E) revealed that 
mice with clinical GVHD demonstrated significantly greater proportions of hCD4+ T cell 
engraftment (85.1 ± 2.0%, n = 10) than mice with subclinical GVHD (45.5 ± 8.4%, n = 3) (P 
< 0.0001) (Fig 3I). Conversely, mice with clinical GVHD demonstrated significantly lower 
proportions of hCD8+ T cell engraftment (12.8 ± 1.7%, n = 10) than mice with subclinical 
GVHD (50.9 ± 8.8%, n = 3) (P < 0.0001) (Fig 3I). Moreover, mice with clinical but not 
subclinical GVHD demonstrated a significantly greater proportion of hCD4+ than hCD8+ T 
cells (P < 0.0001), resulting in higher splenic hCD4+:hCD8+ T cell ratios (8.5 ± 1.7, n = 10) 
than mice with subclinical GVHD (1.0 ± 0.3, n = 3) (P = 0.0418) (Fig 3J). 
 
4.4. Increased serum human IFN-γ is associated with clinical GVHD 
IFN-γ has been implicated in GVHD pathogenesis [25] and correlates to worse disease in 
mice with allogeneic GVHD [26]. Therefore, to determine if humanized NSG mice with 
GVHD demonstrate changes in hIFN-γ, mRNA expression and serum concentrations of this 
cytokine were analyzed by qPCR and ELISA at end-point, respectively. There was a 3-fold 
increase in relative hIFN-γ expression in spleens from mice with clinical GVHD (0.7 ± 0.2, n 
= 3) compared to mice with subclinical GVHD (0.2 ± 0.1, n = 3) (P = 0.0880) (Fig 4A). 
There was also a 1.5-fold increase in relative hIFN-γ expression in livers from mice with 
clinical GVHD (0.9 ± 0.1, n = 3) compared to mice with subclinical GVHD (0.6 ± 0.3, n = 3) 
(P = 0.2576) (Fig 4B). However, small intestines from humanized mice with subclinical 
GVHD or clinical GVHD demonstrated similar relative hIFN-γ expression (0.7 ± 0.3 vs 0.9 ± 
0.1, n = 3) (P = 0.5907) (Fig 4C). Notably, mice with clinical GVHD demonstrated 
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significantly increased serum human IFN-γ concentrations (42.9 ± 2.7 ng/mL, n = 10) 
compared to mice with subclinical GVHD (25.0 ± 5.5 ng/mL, n = 3) (P = 0.0155) (Fig 4D). 
 
4.5. Increased intestinal hIL-17 is associated with clinical GVHD 
IL-17 exacerbates GVHD in allogeneic mouse models of this disease [27,28] and in HSCT 
patients [29]. Whilst, FoxP3 Treg cells exert anti-inflammatory effects in allogeneic [8] and 
humanized mouse models [30], as well as in humans [31] to prevent GVHD. To further 
explore potential immunological differences between humanized NSG mice with subclinical 
or clinical GVHD, relative mRNA expression of hIL-17 and hFoxP3 in the spleen, liver and 
small intestine was assessed by qPCR at end-point.  
Relative splenic hIL-17 expression in mice with clinical GVHD (0.5 ± 0.2, n = 3) was 40% 
lower compared to mice with subclinical GVHD (1.3 ± 0.5, n = 3) (P = 0.2505) (Fig 5A). 
However, hepatic hIL-17 expression was similar between mice with clinical GVHD (1.5 ± 
0.9, n = 3) and subclinical GVHD (1.2 ± 0.2, n = 3) (P = 0.7717) (Fig 5B). Notably, intestinal 
hIL-17 expression was evident in mice with clinical GVHD (1.8 ± 0.4, n = 3) but was absent 
in mice with subclinical GVHD (0.0 ± 0.0, n = 3) (Fig 5C).  
Relative splenic hFoxP3 expression was similar in humanized mice with subclinical GVHD 
(1.2 ± 1, n = 3) or clinical GVHD (0.6 ± 0.2, n = 3) (P = 0.5669) (Fig 5D). Relative hepatic 
hFoxP3 expression was also similar in humanized mice with subclinical GVHD (1.3 ± 0.5, n 
= 3) or clinical GVHD (0.6 ± 0.2 and 2.0 ± 0.8, n = 3) (P = 0.4838) (Fig 5E). However, there 
was a 17-fold but variable increase in intestinal hFoxP3 expression in mice with clinical 
GVHD (0.5 ± 0.3, n = 3) compared to mice with subclinical GVHD (0.03 ± 0.01, n = 3) (P = 
0.2020) (Fig 5F). 
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5. DISCUSSION 
Humanized NSG mouse models of GVHD are used as preclinical models to test potential 
therapeutics [10], however these models have not been fully characterized. The current study 
compared humanized NSG mice with subclinical and clinical GVHD, which paralleled the 
degree of histological disease. Notably, mice with clinical GVHD exhibited greater splenic 
hCD4+:hCD8+ T cell ratios, serum hIFN-γ concentrations and intestinal hIL-17 expression 
than mice with subclinical GVHD. However, it should be noted that in two other independent 
experiments with hPBMCs from two different donors all NSG mice developed clinical 
GVHD (data not shown).  
Humanized mice with a clinical score < 3 were defined as having subclinical GVHD, and 
only showed signs of mild to moderate fur ruffling and/or hunching only at rest. These two 
criteria compared to the other three criteria used are relatively subjective [32], and thus may 
be attributed to events such as being recently awoken rather than GVHD per se. Analysis of 
liver, small intestine and skin revealed that all humanized NSG mice had histological 
evidence of GVHD (leukocyte infiltration, apoptosis and/or tissue damage). Although the 
leukocyte infiltrates in these tissues were not assessed, previous studies have confirmed 
infiltrates comprise hCD45+ leukocytes [14] predominantly hCD3+ T cells [33,34], 
comprising hCD4+ and hCD8+ T cells [35]. Of note, histological evidence of GVHD was 
more apparent in humanized mice with clinical GVHD compared to those with subclinical 
GVHD. The reduced histological GVHD in mice with subclinical GVHD is similar to that 
observed in the livers [33,34,36,37] and small intestine [33,38] of humanized mice following 
various treatments to prevent GVHD. To this end, the current study provided the opportunity 
to examine differences in humanized mice with subclinical versus clinical GVHD, and to 
determine factors that correspond with clinical GVHD development. However, the lung and 
bone marrow are also affected in the humanized NSG mouse model of GVHD [14,35]. Thus, 
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future studies could also compare these tissues in humanized NSG with subclinical and 
clinical GVHD. 
Both humanized NSG mice with subclinical or clinical GVHD were engrafted with similar 
proportions of human leukocytes as shown indirectly by histology of spleens and directly by 
flow cytometry of peripheral blood (week 3) and spleens (at end-point). However, the splenic 
hCD4+:hCD8+ T cell ratios were significantly greater in humanized mice with clinical GVHD 
compared to mice with subclinical GVHD. This finding is consistent with observations that 
disease development in humanized NSG mice is mediated by hCD4+ T cells [14,39]. 
Furthermore, the high CD4+:CD8+ T cell ratios in humanized mice with clinical GVHD 
parallels with studies in humans, in which high CD4+:CD8+ T cell ratios indicate greater 
disease severity [40,41]. These observations contrast other findings in humanized NSG mice, 
where increased hCD4+:hCD8+ T cell ratios correlated with reduced disease severity 
following IL-21 blockade to prevent GVHD [42]. However, this treatment reduced the 
number of hCD4+ (and hCD8+) T cells, indicating that the absolute number of hCD4+ T cells 
may also be important for GVHD development. Additionally, a recent study by Brehm, et al. 
[43] demonstrated similar CD4:CD8 ratios in NSG mice and NSG mice deficient in both 
MHC class I and II, despite MHC class I/II knockout mice showing delayed GVHD 
development.  
Serum hIFN-γ concentrations were significantly increased in humanized NSG mice with 
clinical GVHD compared to those with subclinical GVHD. There was also a trend of 
increased hIFN-γ expression in the spleens and livers of mice with clinical GVHD. Reduced 
serum IFN-γ has been used as a marker to demonstrate a reduction in disease severity in 
allogeneic [44] and humanized mouse models [23,45] following treatments to prevent 
GVHD. However, the current study is the first to demonstrate that increased serum hIFN-γ 
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concentrations in humanized mice are associated with clinical GVHD. A recent study by Ehx, 
et al. [46] confirms our previous findings [23], that CD8+ T cells are the prominent producers 
of hIFN-γ in NSG mice, but CD4+ T cells have also been shown to produce hIFN-γ [35]. 
Therefore, it would be of value to determine if blockade or knockdown of hIFN-γ prevents 
GVHD in humanized NSG mice to directly establish a role for this cytokine in this disease 
model. 
The current study further demonstrated the presence of hFoxP3+ Tregs in the spleens, livers 
and small intestines of humanized NSG mice. This data parallels earlier studies that 
demonstrated the presence of Treg cells in blood, spleens and livers of humanized NSG mice 
[19]. Collectively, these studies demonstrate that hFoxP3+ Tregs can traffic to target organs 
in this humanized mouse model of GVHD. This is important, as Treg cells need to migrate to 
target organs to interact with effector T cells to promote anti-inflammatory effects and reduce 
GVHD severity [47]. In the current study there was a trend of increased FoxP3+ Tregs in the 
small intestines of mice with clinical GVHD compared to subclinical GVHD. Although this 
result is contrary to expectations, it may reflect a compensatory attempt to suppress the 
effector T cells mediating intestinal damage in mice with clinical GVHD. Alternatively, the 
increased intestinal FoxP3 expression may represent FoxP3lo expressing T cells, which can 
differentiate to Th17 cells [48], consistent with the hIL-17 expression in the small intestines 
of mice with clinical GVHD compared to mice with subclinical GVHD. This increased 
intestinal IL-17 expression is consistent with the role of IL-17 in GVHD development [27]. 
Moreover, depletion of donor Th17 cells can delay GVHD [28]. However, the role of IL-17 
in GVHD is complicated, with IL-17 also showing a protective role in intestinal GVHD [49]. 
Thus, the increased IL-17 expression in the small intestines of mice with clinical GVHD may 
reflect increased pathology or a compensatory mechanism to protect against intestinal GVHD 
in these mice.  
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In conclusion, the current study identified increases in splenic hCD4+:hCD8+ T cell ratios, 
serum hIFN-γ concentrations and intestinal hIL-17 in humanized mice with clinical GVHD 
compared to mice with subclinical GVHD, consistent with observations in human HSCT 
recipients with GVHD. The cellular and molecular changes identified in the current study 
could also be used as potential biomarkers in this preclinical model. Furthermore, this data 
provides insight into GVHD development in this preclinical model, which may aid 
investigation of potential therapeutics due to the ability to target human cells and investigate 
human immune responses in these humanized mice. 
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FIGURE LEGENDS 
Figure 1. Clinical GVHD development varies in humanized mice. 
(A-C) NSG mice were injected i.p. with PBS (control) (n = 6) or 10 x 106 hPBMCs in PBS (n 
= 13) and monitored for GVHD over 8 weeks. NSG mice were monitored for (A) clinical 
score, (B) weight loss and (C) survival. Humanized mice with subclinical GVHD (n = 3) 
were defined as having a clinical score < 3 and mice with clinical GVHD (n = 10) were 
defined as having a clinical score ≥ 3. Data represents (A, B) group means ± SEM, or (C) 
percent survival from two experiments using a single hPBMC donor; *** P < 0.0001 
compared to control mice, †† P < 0.01 and ††† P < 0.0001 compared to mice with subclinical 
GVHD. 
Figure 2. Increased histological damage and leukocyte infiltration is associated with 
clinical GVHD. 
Tissue sections (spleen, liver, small intestine and skin) from control mice (left panels) or 
hPBMC-injected mice with subclinical GVHD (middle panels) or clinical GVHD (right 
panels) at end-point were stained with haematoxylin and eosin, and images captured by 
microscopy. Each image is representative of three mice per group from two experiments 
using a single hPBMC donor; bar represents 100 μm. 
Figure 3. Humanized mice with clinical GVHD exhibit increased human CD4+:CD8+ T cell 
ratios. 
(A-D) Blood (3 weeks post-hPBMC injection) and (E-F) spleens (end-point) from mice were 
analyzed by flow cytometry. Representative gates and quadrant regions are shown (A, E). (B-
F) hCD45+ leukocytes (hCD45+ mCD45-) are expressed as a percentage of total leukocytes 
(hCD45+ mCD45- + hCD45- mCD45+). (C, G) hCD3+ hCD19- cells and (D, H) hCD3- 
hCD19- cells are expressed as a percentage of hCD45+ leukocytes. hCD4+ and hCD8+ T cells 
are expressed as a percentage of hCD3+ T cells and (J) used to determine hCD4+:hCD8+ T 
cell ratios. (B-D, C-J) Data represents group means ± SEM; symbols represent individual 
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mice from two experiments using a single hPBMC donor; ** P < 0.005, *** P < 0.0001 
compared to control mice; † P < 0.05, ††† P < 0.0001 compared to corresponding cells in mice 
with subclinical GVHD; ### P < 0.0001 compared to corresponding CD8+ T cells.  
Figure 4. Humanized mice with clinical GVHD demonstrate increased serum hIFN-γ 
concentrations. 
The relative expression of hIFN-γ in (A) spleens, (B) livers and (C) small intestines from 
mice with subclinical and clinical GVHD at end-point were examined by qPCR. Data 
represents group means ± SEM (n = 3 per group); symbols represent individual mice from 
two experiments using a single hPBMC donor. (D) Serum hIFN-γ concentrations were 
analyzed by ELISA. Data represents group means ± SEM (subclinical GVHD n = 3, clinical 
GVHD n = 5); ** P < 0.005 compared to mice with subclinical GVHD. 
Figure 5. Humanized mice with clinical GVHD demonstrate increased intestinal hIL-17. 
The relative expression of (A-C) hIL-17 and (D-F) hFoxP3 in (A, D) spleens, (B, E) livers 
and (C, F) small intestines from mice with subclinical and clinical GVHD at end-point were 
examined by qPCR. Data represents group means ± SEM (n = 3 per group); symbols 
represent individual mice from two experiments using a single hPBMC donor.  
 
Table 1. Scoring system for clinical GVHD.  
Mice are assigned a score out of 2 for each of the criterion outlined to give a total score of 10 
(as previously described [23]). Humanized mice with clinical score < 3 were defined as 
subclinical GVHD, and mice with a clinical score ≥ 3 were defined as clinical GVHD.  
GRADE 0 1 2 
Weight loss
a < 5% 5% to 10% > 10% 
Posture Normal Hunching noted only at rest Severe hunching 
Activity Normal Mild to moderately decreased Stationary unless stimulated 
Fur texture Normal Mild to moderate ruffling Severe ruffling 
Skin Integrity Normal Scaling of paws/tail Obvious areas of involved skin 
a
 Percent of starting weight (day 0). 
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